Mr. Chandu 1i. Patel, 1B'Bilbu'n, N.J., and f'Vlrs. Hanna D.
Syiwestrocvi~c, t3ernardsvil(c, hl.J.
In drug safety evaluation a compound may prodme. ( I ) acute or chronic lesions which are not observed in the control group an~3 which occur infreyuently in untreated animals; (2) an increased incidence of lesions which occur in normal untreated animals including tumors. In both categories, but particularly in the second group, the types of lesions, which may be observed spontaneously in untreated, as well as at higher incidence levels in treated animals of a given species, are moderated by the genetic profile of the strain, species and individual anirr~l.
Before considering pitfalls in experimental design, we briefly consider the incidence for any abnormality which occurs in treated versus control animals and is needed to be significant at probability levels of O.OS, O.O1 and O.Ot~l (Table 1 ) . As the size of two samples being compared increases, the proportion of the abnormality incidence, required to be statistically significant, decreases. For example, with four animals per group and zero incidence in the control group, 100°r° of the animals in the treated group must be affected with a given lesion for the difference to be statistically significant. With 30 animals per group and zero incidence in the control group, only about 17°fo of the animals in the treated group must be affected for the difference to be significant.
I
Dealing with a large group of animals in a drug safety evaluation study, it is tempting to reduce the workload by basing pathologic evaluations on sub-samples taken from control and treated groups. The most acceptable means of distribution of animals into control and treatment groups is by prior identification
